Orchestra BioMed is launching a public offering of common stock to finance its pivotal clinical trials, with underwriters holding a 30-day option for an additional 15% of shares.
The company launched an underwritten public offering of new common shares, with a 30-day option for underwriters to buy up to 15% additional shares. New share issuance dilutes existing holders, and biotech offerings announced without size or price typically pressure the stock on announcement. No offering size is disclosed and completion is uncertain, which caps the certainty of the move.
Orchestra BioMed Holdings, Inc. has commenced an underwritten public offering of its common stock. The company plans to use the net proceeds to fund its AVIM Therapy and Virtue SAB clinical programs, including the Backbeat and Virtue trials. Underwriters have been granted a 30-day option to purchase up to an additional 15% of the shares sold in the offering.
Issuing new common stock dilutes existing shareholders, which typically pressures the share price, though the size and price of the offering had not been announced and completion is not assured.